Browse the evidence

Obesity involves molecular mechanisms, including metabolic memory and epigenetic modifications, that actively hinder weight loss and promote weight regain.

If you are struggling to lose weight despite diet and exercise, recognize that your body has biological defenses (like metabolic memory and hormonal shifts) that actively work to restore previous weight. This is not a failure of willpower but a known physiological response. Addressing these barriers may require a multidisciplinary approach, potentially including medical interventions, rather than just stricter dieting.

Epigenetic changes, such as DNA methylation and histone modifications, can persist after weight loss and contribute to weight regain.

Weight loss can trigger long-lasting epigenetic changes that make your body more prone to regaining weight. This means maintaining weight loss might require ongoing effort and potentially medical support, as your body's 'default setting' may have shifted.

Adipose tissue dysfunction, characterized by chronic low-grade inflammation and insulin resistance, creates a self-perpetuating cycle that promotes obesity.

Excess fat, especially around the abdomen, is not just inert storage but an active organ that releases inflammatory signals. These signals can cause insulin resistance and further fat storage, creating a cycle that is hard to break without addressing the underlying inflammation.

GLP-1 receptor agonists may interact with oral systemic cancer therapies by delaying gastric emptying, potentially altering absorption kinetics (time to peak concentration) without necessarily changing total drug exposure.

If you take oral cancer pills along with GLP-1 drugs (like Ozempic), tell your doctor. The GLP-1 drug might slow down how fast your cancer pills are absorbed. This doesn't always mean the treatment won't work, but your doctor needs to know to monitor you closely.

GLP-1 receptor agonist consumption in Brazil is driven by socioeconomic capacity and access rather than epidemiological need, as evidenced by a significant positive correlation with GDP per capita and no correlation with obesity prevalence.

In Brazil, access to GLP-1 drugs like semaglutide is currently determined by your state's economic wealth rather than your obesity rates. Public health policy has excluded these drugs from free coverage, creating a market where only those with higher income can afford them, regardless of medical need.

Semaglutide is the predominant GLP-1 RA in Brazil, driving the majority of sales growth and adverse event reports, with significant off-label use for weight loss.

Semaglutide is the most widely used GLP-1 drug in Brazil. A significant portion of its use is off-label for weight loss, which generates specific adverse event reports and requires careful monitoring.

GLP-1 receptor agonist therapy (semaglutide/tirzepatide) is increasingly driving referrals for post-weight-loss body contouring, with referral volumes growing faster than those from lifestyle modification or bariatric surgery.

If you are using GLP-1 medications like Ozempic or Mounjaro, be aware that rapid weight loss often leads to excess skin. You may need to consult a plastic surgeon for body contouring procedures. This is a common and expected outcome of significant weight loss via these medications.

In type 2 diabetes, worsening chronic glycaemic control (higher HbA1c) shifts endogenous GIP action from insulinotropic to glucagonotropic, strengthening the correlation between GIP and glucagon secretion while weakening its correlation with insulin.

For people with Type 2 Diabetes, the effectiveness of the body's natural GIP response depends heavily on how well blood sugar is controlled. If HbA1c is high, GIP may contribute to higher glucagon (raising blood sugar) rather than helping insulin. This suggests that managing baseline blood sugar is crucial for optimizing natural hormonal responses.

Expanding first-level genetic screening for obesity to include POMC and MC3R genes is necessary to maximize diagnostic yield and identify patients with intermediate susceptibility phenotypes who are missed by standard panels.

If you have obesity and standard genetic tests came back negative, ask your doctor about expanded testing for POMC and MC3R genes. This can reveal if you have a specific biological susceptibility that might affect how your body handles energy, potentially guiding more personalized treatment strategies.

GLP-1 and dual GIP/GLP-1 receptor agonists exert neuropsychiatric effects by modulating central neurotransmitter systems (dopamine, serotonin, GABA, glutamate) and promoting neuroplasticity, potentially treating addiction, depression, and cognitive decline.

GLP-1 and dual agonists (like semaglutide and tirzepatide) do more than just suppress appetite; they interact with brain receptors that regulate mood, reward, and memory. While they are primarily prescribed for diabetes and weight loss, research suggests they may also help with conditions like addiction, depression, and cognitive decline by balancing neurotransmitters like dopamine and serotonin. However, patients should be aware that while serious psychiatric side effects are rare and not consistently linked to the drugs, isolated reports of mood changes exist, so monitoring mental health is recommended.

GLP-1RAs are associated with rare but serious adverse events including acute pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, though causal relationships for some (like thyroid cancer) are not confirmed in humans.

Be aware of rare but serious side effects like pancreatitis, gallbladder disease, and worsening of diabetic retinopathy (especially if you have pre-existing eye disease). While the risk of thyroid cancer is a concern in animal studies, no human cases have been confirmed. Report any severe abdominal pain or vision changes to your doctor.

Topical cosmetic peptides (e.g., GHK-Cu, Matrixyl, Argirelin) reduce wrinkles and improve skin firmness with excellent safety profiles, though effects are modest and require consistent long-term use.

Topical peptides like GHK-Cu, Matrixyl, and Argirelin can help reduce wrinkles and improve skin firmness when applied consistently over 8-12 weeks. They are generally safe and well-tolerated, but the effects are modest compared to injectable treatments. Regular use is necessary to maintain benefits.

High-dose tirzepatide (10–15 mg/week) is associated with a statistically significant increase in the risk of acute kidney injury (AKI) compared to control treatments.

If you are prescribed high-dose tirzepatide (10-15 mg/week), be aware of a small but statistically significant increased risk of acute kidney injury. Stay well-hydrated, especially if you experience gastrointestinal side effects like nausea or diarrhea, as volume depletion can trigger AKI. Monitor your kidney function as recommended by your doctor, and report any sudden changes in urination or swelling immediately.

Chronic low-grade inflammation and oxidative stress in MASLD drive atrial structural and electrical remodeling, creating an arrhythmogenic substrate for AF.

Treating MASLD involves more than just liver health; it requires addressing systemic inflammation and oxidative stress to protect the heart from structural remodeling that leads to AF.

Implantation of alginate-encapsulated engineered HEKGLP-1 cells in mice, activated by endogenous or exogenous melatonin, produces GLP-1 specifically during the night phase, restoring normoglycemia in type-2 diabetic models.

This research proposes a future therapy where genetically engineered cells are implanted and protected in a capsule. These cells produce the diabetes drug GLP-1 only when melatonin levels are high (at night). Patients could take oral melatonin to control how much GLP-1 is produced, potentially allowing for once-daily dosing instead of weekly injections. This is currently only proven in mice.

In obese patients without preexisting osteoarthritis, GLP-1 receptor agonist use is associated with an increased incidence of new hip and knee OA diagnoses and conversion to total knee arthroplasty within one year.

If you are obese but do not have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist is associated with a higher risk of being diagnosed with new OA or needing knee replacement surgery within a year. This is unexpected given the weight loss benefits, and researchers suggest it might be due to increased physical activity stressing the joints. If you are considering these medications, discuss your joint health history with your doctor, and be aware that the benefits for joint health may primarily apply to those who already have OA.

The proposed mechanism for this hearing loss is the suppression of matrix metalloproteinase-9 (MMP-9) by exendin-4 derivatives, leading to micro-platelet-erythrocyte clot formation and occlusion of cochlear micro-circulation.

This mechanism is currently theoretical. While it provides a plausible biological explanation for why Lixisenatide might affect hearing, it has not been directly proven in human trials yet.

Tirzepatide (TZP) administration causes bone loss in obese diabetic mice by reducing gut microbiota biodiversity, specifically depleting Lachnospiraceae, which leads to lower levels of the metabolite evodiamine and subsequent increased osteoclastogenesis.

If you are taking Tirzepatide for diabetes or obesity, be aware that it may reduce bone density in your hips/femurs by altering gut bacteria. Discuss bone health monitoring with your doctor. The study suggests that maintaining gut health (specifically Lachnospiraceae bacteria) might protect bone, though probiotic supplementation is not yet a standard prescription.

Monogenic diabetes, representing 1-4% of diabetes cases in infants and young adults, is frequently misdiagnosed as Type 1 or Type 2 diabetes, leading to inappropriate therapeutic management and worsened prognosis.

If a child or young adult is diagnosed with diabetes, ask if genetic testing for monogenic forms has been considered. Misdiagnosis as T1 or T2 can lead to incorrect treatment and worse outcomes, as monogenic diabetes often requires specific therapies different from standard insulin or oral agents.

Machine learning-guided optimization of triple agonist peptides (GCGR, GLP1R, GIPR) using Graph Attention Networks and genetic algorithms generates peptide sequences with high predicted binding affinity across all three targets, demonstrating superior computational performance over traditional Convolutional Neural Networks for GCGR prediction.

This research does not yet offer a direct treatment for patients. It describes a computational method to design better diabetes and obesity drugs. The key takeaway is that using advanced AI (Graph Attention Networks) to design peptides that target three metabolic receptors (GCGR, GLP1R, GIPR) simultaneously is more effective than older methods. This could lead to more potent drugs in the future, but no such drug is currently available for clinical use based on this paper alone.

Knockout of the lineage-specific microprotein Adipocyte-smORF-1183 significantly impairs adipocyte differentiation and reduces lipid droplet formation by approximately 50% in 3T3-L1 cells.

This research identifies a specific microprotein (Adipocyte-smORF-1183) in mouse fat cells that helps store fat. Knocking it out reduces fat storage by half in these cells. This is a basic science discovery about how fat cells work and does not currently translate to a human treatment or supplement.

Perioperative GLP-1 receptor agonist therapy does not significantly reduce periprosthetic joint infection or revision rates in patients undergoing total knee arthroplasty.

If you are having knee replacement, current evidence does not show that GLP-1 agonists reduce infection or revision risk. Discuss with your surgeon, but do not expect the same benefits seen in hip surgery.

Inhibiting miR-30e-5p using antagomirs reduces atherosclerosis in obese mouse models by restoring SLC7A11 expression and improving endothelial mitochondrial function.

While not yet a human treatment, this finding suggests that future therapies could target the specific signals fat cells send to blood vessels. For now, maintaining a healthy weight remains the most effective way to prevent these damaging signals from accumulating.

Inadvertent exposure to GLP-1 receptor agonists during pregnancy does not appear to pose a significant teratogenic risk, with congenital abnormality rates in exposed pregnancies being lower than or comparable to placebo groups.

If you took a GLP-1 medication (like Ozempic or Wegovy) before knowing you were pregnant, current data from clinical trials does not show an increased risk of birth defects compared to women who did not take these medications. You should stop the medication as soon as you know you are pregnant and consult your doctor for standard prenatal care.